Trastuzumab is significantly more effective alone or in combination with lapatinib than is lapatinib alone for the treatment of human epidermal growth factor receptor 2-positive breast cancer in patients receiving neoadjuvant chemotherapy, according to findings from two randomized phase III trials.The studies - GeparQuinto and the NeoALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimization) trial - underscore the value of testing new therapies in the neoadjuvant setting.In the GeparQuinto...